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Introduction

Results

With the increased use of screening mammography, the incidence of ductal carcinoma in situ (DCIS)
has increased substantially and it currently accounts for 20–30% of newly diagnosed breast
carcinomas in United States. Breast conserving therapy with or without radiotherapy is the accepted
treatment for most cases of DCIS. However, the local recurrence rate with such therapy ranges
from10 to 40% with half of these patients developing invasive carcinoma. Tamoxifen, used as an
adjuvant systemic therapy for DCIS, does not increase overall survival and data on reduction of local
recurrence rates are conflicting.

Sixteen DCIS patients underwent some form of recurrence: 8 recurred to DCIS, while the other 8
recurred with progression to invasive breast cancer. Nearly ninety percent of DCIS patients (7/8)
that underwent recurrence to invasive breast cancer had reduced or absent levels of stromal Cav-1.
Representative examples of Cav-1 immunostaining are shown in (Figure 1). The absence of stromal
Cav-1 (score = 0) was specifically associated with early disease progression to invasive breast cancer,
with reduced time to recurrence and higher recurrence rate. All DCIS patients with an absence of
stromal Cav-1 underwent some form of recurrence (5/5) and the majority (4/5) underwent
progression to invasive breast cancer (Figure 2). This represents an overall cumulative incidence rate
of 100% for recurrence and 80% for progression. An absence of stromal Cav-1 in DCIS lesions was
also specifically associated with the presence of inflammatory cells. Inflammation (the presence of
lymphocytes and/or macrophages) was specifically associated with DCIS progression to invasive
breast cancer (Figure 3) however this effect was strictly dependent on stromal Cav-1 levels.
Conversely, ninety-seven percent of DCIS patients with high levels of stromal Cav-1 (score = 2) did
not show any invasive recurrence over the duration of follow-up (4–208 mo), and 89% of such patients are estimated to remain free of invasive recurrence, even after 15 y.

The current classification for DCIS based on nuclear grade, architectural differentiation and
presence of necrosis, does not adequately predict the likelihood of recurrence after breast
conserving therapy. Therefore, there is a critical need to identify novel predictors of DCIS
progression and potential targets for therapy.
Recently, we showed that an absence of stromal (caveolin 1) Cav-1 expression in human breast
cancers is a powerful single independent predictor of early disease recurrence, metastasis and poor
clinical outcome. However, it remains unknown whether stromal Cav-1 levels play any role in the
progression of DCIS. The aim of this study was to evaluate the stromal expression of Cav-1 in a
cohort of DCIS patients treated with wide-excision and close follow-up and examined the
association between stromal Cav-1 expression and clinicopathological variables, DCIS recurrence or
progression to invasive breast cancer.

Figure 2. Kaplan-Meier curves for stromal Cav-1 status and time to overall recurrence among DCIS patients. Note that an absence or reduction of stromal Cav-1 is strongly associated with an increase in
progression to invasive breast cancer. On the left, patients were stratified into three different groups. On
the right, patients with low or absent Cav-1 were considered as a single group. p values (log rank test)
are as shown.

Material and Methods
DCIS breast tissues were obtained from the Surgical Pathology files at the Thomas Jefferson
University. Seventy-eight cases for which histologic slides and blocks were available were included in
the study. Clinical and treatment information was extracted by chart review. All patients were
treated by the same surgeon (Gordon F. Schwartz, M.D.), undergoing surgical excision only, and all
had negative margins (= or > 10 mm) at the conclusion of surgical excision or re-excision. None of
the patients underwent radiation therapy, or were given tamoxifen. The median follow-up time for
these patients was 146.8 months (12.23 years). For each case, histologic pattern (solid, cribriform,
papillary, micropapillary, comedo), nuclear grade, presence of necrosis and inflammation were
recorded. Cav-1 expression in the tumor stroma was assessed by a standard immunoperoxidase
method (anti-caveolin-1 IgG, BD Biosciences,San Jose, CA; 1:50 dilution). The staining was scored
semi-quantitatively as negative (0; no staining), weak (1; either diffuse weak staining or strong
staining in less than 30% of stromal cells) and strong (2; defined as strong staining of 30% or more
of the stromal cells). All hypothesis testing was performed using the Fisher exact test or the
Kruskal-Wallis test, depending on the discrete or continuous nature of the other factors.

Figure 3. Kaplan-Meier curves for inflammation and time to DCIS recurrence and invasive recurrence
among ER(+) DCIS patients. Note that inflammation is associated with an increase in progression to invasive breast cancer, but not simple DCIS recurrence. p values (log rank test) are as shown.

Figure 1 Cav-1 immunohistochemical staining in normal breast and ductal carcinoma
in situ (DCIS).A, Focal weak staining in stromal fiboblasts in the terminal duct lobular
unit. B, Score 0 (no staining) in DCIS. C, Weak expression of stromal Cav-1 (score
1) in DCIS. D, Strong diffuse staining in stromal fibroblasts representing score 2.
In all panels myoepithelial and endothelial cells exhibit strong staining. (original
magnification 400X (panel A) and 200X (panels B-D))

Conclusions
Stromal Cav-1 may represent a valuable new biomarker for dividing DCIS patients into
high-risk and low-risk groups at diagnosis, facilitating their treatment stratification.

